1-3 of 3
Gregg Fine
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

A phase 1 study of obinutuzumab induction followed by 2 years of maintenance in patients with relapsed CD20-positive B-cell malignancies

Clinical Trials & Observations
Laurie H. Sehn, Sarit E. Assouline, Douglas A. Stewart, Joy Mangel, Randy D. Gascoyne, Gregg Fine, Susan Frances-Lasserre, David J. Carlile, Michael Crump
Journal: Blood
Blood (2012) 119 (22): 5118–5125.
https://doi.org/10.1182/blood-2012-02-408773
Published: 2012
Journal Articles

Randomized Phase II Trial Comparing GA101 (Obinutuzumab) with Rituximab in Patients with Relapsed CD20 Indolent B-Cell Non-Hodgkin Lymphoma: Preliminary Analysis of the GAUSS Study

Laurie H. Sehn, MD, MPH, Andre Goy, MD, Fritz C. Offner, MD, PhD, Giovanni Martinelli, MD, Jonathan Friedberg, MD, Susan F. Lasserre, MSc, Gregg Fine, MD, Oliver W. Press, MD, PhD
Journal: Blood
Blood (2011) 118 (21): 269.
https://doi.org/10.1182/blood.V118.21.269.269
Published: 2011
Journal Articles

Final Results of a Single Arm Phase III Multicenter, Open-Label Study of Rituximab Administered by Faster Infusion in Patients with Previously Untreated Diffuse Large-B Cell (DLBCL) or Follicular Non-Hodgkin's Lymphoma (FL)

Shaker R. Dakhil, MD, Robert Hermann, MD, Akiko Chai, MS, Deborah Hurst, MD, Gregg Fine, MD, Paul Richards, MD
Journal: Blood
Blood (2011) 118 (21): 2703.
https://doi.org/10.1182/blood.V118.21.2703.2703
Published: 2011